Raf kinase inhibitor protein expression combined with peritoneal involvement and lymphovascular invasion predicts prognosis in Dukes' B colorectal cancer patients

Histopathology

Volumn 62, Issue 3, 2013, Pages 505-510

  Doyle, Brendan ^a,e   Hagan, Suzanne ^a,i   Al Mulla, Fahd ^b   Scott, Lucy ^c   Harden, Sharon ^d   Paul, Jim ^d   Mulcahy, Hugh ^e   Murray, Graeme I ^f   Sheahan, Kieran ^e   O'Sullivan, Jacintha ^g   Kolch, Walter ^h  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b KUWAIT UNIVERSITY   (Kuwait)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^e ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^f UNIVERSITY OF ABERDEEN   (United Kingdom)

^g ST JAMES S HOSPITAL   (Ireland)

^h UNIVERSITY COLLEGE DUBLIN   (Ireland)

ⁱ GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

Author keywords

Colorectal cancer; Dukes's B; Prognosis; Raf kinase inhibitor protein; Stage II

Indexed keywords

PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN;

ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SPECIFIC SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PERITONEUM METASTASIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN METHYLATION; PYROSEQUENCING; RECEPTOR DOWN REGULATION; RISK FACTOR; TISSUE MICROARRAY; TISSUE SECTION;

COLORECTAL NEOPLASMS; DNA METHYLATION; DOWN-REGULATION; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM STAGING; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROGNOSIS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872661634     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12014     Document Type: Article

References (45)

1. Yeung K, Seitz T, Li S et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 1999; 401; 173-177.
2. Yeung KC, Rose DW, Dhillon AS et al. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol. Cell. Biol. 2001; 21; 7207-7217.
3. Lorenz K, Lohse MJ, Quitterer U. Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 2003; 426; 574-579.
4. Eves EM, Shapiro P, Naik K, Klein UR, Trakul N, Rosner MR. Raf kinase inhibitory protein regulates aurora B kinase and the spindle checkpoint. Mol. Cell 2006; 23; 561-574.
5. Granovsky AE, Rosner MR. Raf kinase inhibitory protein: a signal transduction modulator and metastasis suppressor. Cell Res. 2008; 18; 452-457.
6. Hagan S, Al-Mulla F, Mallon E et al. Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin. Cancer Res. 2005; 11; 7392-7397.
7. Fu Z, Kitagawa Y, Shen R et al. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate 2006; 66; 248-256.
8. Al-Mulla F, Hagan S, Behbehani AI et al. Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J. Clin. Oncol. 2006; 24; 5672-5679.
9. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 2007; 18; 581-592.
10. Fernandez E, La Vecchia C, Gonzalez JR, Lucchini F, Negri E, Levi F. Converging patterns of colorectal cancer mortality in Europe. Eur. J. Cancer 2005; 41; 430-437.
11. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 2004; 350; 2343-2351.
12. Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br. J. Surg. 2008; 95; 1029-1036.
13. Towler BP, Irwig L, Glasziou P, Weller D, Kewenter J. Screening for colorectal cancer using the faecal occult blood test, hemoccult. Cochrane Database Syst. Rev. 2000; CD001216.
14. Burton S, Norman AR, Brown G, Abulafi AM, Swift RI. Predictive poor prognostic factors in colonic carcinoma. Surg. Oncol. 2006; 15; 71-78.
15. Quasar Collaborative G, Gray R, Barnwell J et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370; 2020-2029.
16. Kuebler JP, Wieand HS, O'Connell MJ et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J. Clin. Oncol. 2007; 25; 2198-2204.
17. Andre T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 2009; 27; 3109-3116.
18. Minoo P, Zlobec I, Baker K et al. Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer. Am. J. Clin. Pathol. 2007; 127; 820-827.
19. Zlobec I, Baker K, Minoo P, Jass JR, Terracciano L, Lugli A. Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression. Clin. Cancer Res. 2008; 14; 143-148.
20. Al-Mulla F, Hagan S, Al-Ali W et al. Raf kinase inhibitor protein: mechanism of loss of expression and association with genomic instability. J. Clin. Pathol. 2008; 61; 524-529.
21. Minoo P, Baker K, Goswami R et al. Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut 2006; 55; 1467-1474.
22. Beach S, Tang H, Park S et al. Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene 2008; 27; 2243-2248.
23. Ren G, Baritaki S, Marathe H et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor rkip in breast and prostate cancer. Cancer Res. 2012; 72; 3091-3104.
24. Shepherd NA, Baxter KJ, Love SB. The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. Gastroenterology 1997; 112; 1096-1102.
25. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl Cancer Inst. 2004; 96; 1420-1425.
26. Petersen VC, Baxter KJ, Love SB, Shepherd NA. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut 2002; 51; 65-69.
27. Eisenberg B, Decosse JJ, Harford F, Michalek J. Carcinoma of the colon and rectum: the natural history reviewed in 1704 patients. Cancer 1982; 49; 1131-1134.
28. Nicastri DG, Doucette JT, Godfrey TE, Hughes SJ. Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. J. Mol. Diagn. 2007; 9; 563-571.
29. Sobrero A, Köhne CH. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? Lancet Oncol. 2006; 7; 515-517.
30. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst. Rev. 2008; CD005390.
31. Andre T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 2009; 27; 3109-3116.
32. Lennon AM, Mulcahy HE, Hyland JM et al. Peritoneal involvement in stage II colon cancer. Am. J. Clin. Pathol. 2003; 119; 108-113.
33. Langner C, Harbaum L, Pollheimer MJ et al. Mucinous differentiation in colorectal cancer-indicator of poor prognosis? Histopathology 2012; 60; 1060-1072.
34. Compton CC, Fielding LP, Burgart LJ et al. Prognostic factors in colorectal cancer College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 2000; 124; 979-994.
35. Talbot IC, Ritchie S, Leighton MH, Hughes AO, Bussey HJ, Morson BC. The clinical significance of invasion of veins by rectal cancer. Br. J. Surg. 1980; 67; 439-442.
36. Blenkinsopp WK, Stewart-Brown S, Blesovsky L, Kearney G, Fielding LP. Histopathology reporting in large bowel cancer. J. Clin. Pathol. 1981; 34; 509-513.
37. Williams GT, Quirke P, Shepherd NA. Royal College of Pathologists, Standards and Datasets for Reporting Cancers; Dataset for colorectal cancer, 2nd edn. Royal College of Pathologists, UK (http://www.rcpath.org/Resources/RCPath/Migrated%20Resources/Documents/G/G049-ColorectalDataset-Sep07.pdf) 2007.
38. Washington K, Berlin J, Branton P et al. College of American Pathologists, Cancer Protocls and Checklists: Protocol for the Examination of Specimens from Patients with Primary Carcinoma of the Colon and Rectum. College of American Pathologists, US (http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2012/Colon_12protocol_3200.pdf) 2011.
39. Di Fabio F, Nascimbeni R, Villanacci V et al. Prognostic variables for cancer-related survival in node-negative colorectal carcinomas. Dig Surg 2004; 21; 128-133.
40. Eckstein R, Ackland S, Brown I et al. Royal College of Pathologists of Australia, Cancer Protocols: colorectal cancer structured reporting protocol. Royal College of Pathologists of Australia (http://www.rcpa.edu.au//static/file/asset%20library/public%20documents/publications/structuredreporting/colorectal%20cancer%20structured%20reporting%20protocol%20for%20web.pdf) 2010.
41. Wang LM, Kevans D, Mulcahy H et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am. J. Surg. Pathol. 2009; 33; 134-141.
42. Zlobec I, Vuong T, Hayashi S et al. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br. J. Cancer 2007; 96; 793-800.
43. Des Guetz G, Uzzan B, Nicolas P et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br. J. Cancer 2006; 94; 1823-1832.
44. Wang Y, Jatkoe T, Zhang Y et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J. Clin. Oncol. 2004; 22; 1564-1571.
45. Al-Mulla F, Behbehani AI, Bitar MS, Varadharaj G, Going JJ. Genetic profiling of stage I and II colorectal cancer may predict metastatic relapse. Mod. Pathol. 2006; 19; 648-658.